MedTrace Logo

Dry Eye Assessment and Management Study

NCT02128763 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 535

Last updated 2022-07-19

Study results available
· View outcomes & findings →

Summary

The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.

Conditions

  • Dry Eye

Interventions

DRUG

Omega-3 supplements

2000 mg EPA and 1000 mg DHA per day

DRUG

Placebo

Olive oil gelcaps manufactured to mimic Omega-3 gelcaps

Sponsors & Collaborators

Principal Investigators

  • Penny A Asbell, MD · University of Tennessee

  • Maureen G Maguire, PhD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-09-05
Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02128763 on ClinicalTrials.gov